Table 2.
Antiretroviral regimens received by the 275 HIV-infected inmates on ART
| ANTIRETROVIRAL DRUGS | n (%) |
|---|---|
| Protease inhibitors (PI) | |
| Atazanavir | 88 (32.0 %) |
| Lopinavir | 51 (18.5 %) |
| Darunavir | 23 (8.4 %) |
| Fosamprenavir | 9 (3.3 %) |
| Saquinavir | 1 (0.4) |
| Total | 172 (62.6 %) |
| Non nucleoside reverse trascriptase inhibitors (NNRTI) | |
| Efavirenz | 50 (18.2 %) |
| Nevirapine | 9 (3.3 %) |
| Rilpivirine | 8 (2.9 %) |
| Etravirine | 5 (1.8 %) |
| Total | 72 (26.2 %) |
| 3 Nucleoside reverse transriptase inhibitors (NRTI) | |
| Abacavir-Lamivudine-Zidovudine | 6 (2.2 %) |
| Integrase inhibitors (INI) | |
| Raltegravir | 24 (8.7 %) |
| CCR5 inhibitors | |
| Maraviroc | 1 (0.4 %) |
| NRTI backbone | |
| Tenofovir disoproxilfumarate-emtricitabine | 194 (70.5 %) |
| Abacavir-lamivudine | 41 (14.9 %) |
| Zidovudine-lamivudine | 12 (4.4 %) |
| Other | 28 (10.2 %) |